scholarly journals Non-Motor Symptoms after One Week of High Cadence Cycling in Parkinson’s Disease

2019 ◽  
Vol 16 (12) ◽  
pp. 2104 ◽  
Author(s):  
Sara A. Harper ◽  
Bryan T. Dowdell ◽  
Jin Hyun Kim ◽  
Brandon S. Pollock ◽  
Angela L. Ridgel
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Depression Symptoms ◽  
Motor Cognition ◽  
Val66met Polymorphism ◽  
Main Effect ◽  
Bdnf Val66met Polymorphism ◽  
Global Cognition ◽  
Non Motor Symptoms ◽  
High Cadence

The objective was to investigate if high cadence cycling altered non-motor cognition and depression symptoms in individuals with Parkinson’s disease (PD) and whether exercise responses were influenced by brain-derived neurotrophic factor (BDNF) Val66Met polymorphism. Individuals with idiopathic PD who were ≥50 years old and free of surgical procedures for PD were recruited. Participants were assigned to either a cycling (n = 20) or control (n = 15) group. The cycling group completed three sessions of high cadence cycling on a custom motorized stationary ergometer. The primary outcome was cognition (attention, executive function, and emotion recognition were assessed via WebNeuro® and global cognition via Montreal Cognitive Assessment). Depression symptoms were assessed via Beck Depression Inventory-II. There was a main effect of time for emotional recognition (p = 0.048), but there were no other changes in cognition or depression symptoms. Regardless of intervention or Val66Met polymorphism, high cadence cycling does not alter cognition or depression symptoms after three sessions in one week.

Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson’s disease

2019 ◽  
Vol 372 ◽  
pp. 112039 ◽  
Author(s):  
Frederic Sampedro ◽  
Juan Marín-Lahoz ◽  
Saul Martínez-Horta ◽  
Javier Pagonabarraga ◽  
Jaime Kulisevsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Val66met Polymorphism ◽  
Cortical Thinning ◽  
Bdnf Val66met Polymorphism

The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease

2005 ◽  
Vol 252 (7) ◽  
pp. 833-838 ◽  
Author(s):  
Th. Foltynie ◽  
S. G. J. Lewis ◽  
T. E. Goldberg ◽  
A. D. Blackwell ◽  
B. S. Kolachana ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Val66met Polymorphism ◽  
Planning Ability ◽  
Bdnf Val66met Polymorphism ◽  
Gender Specific ◽  
Specific Influence

scholarly journals Association of BDNF Val66MET Polymorphism With Parkinson’s Disease and Depression and Anxiety Symptoms

2017 ◽  
Vol 29 (2) ◽  
pp. 142-147 ◽  
Author(s):  
Fernanda Carvalho Cagni ◽  
Clarissa Loureiro das Chagas Campêlo ◽  
Daniel Gomes Coimbra ◽  
Mayara Rodrigues Barbosa ◽  
Luiz Gonzaga Oliveira Júnior ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Anxiety Symptoms ◽  
Depression And Anxiety ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease

2009 ◽  
Vol 16 (11) ◽  
pp. 1240-1245 ◽  
Author(s):  
F. R. Guerini ◽  
E. Beghi ◽  
G. Riboldazzi ◽  
R. Zangaglia ◽  
C. Pianezzola ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population

2003 ◽  
Vol 53 (6) ◽  
pp. 823-823 ◽  
Author(s):  
Anna Håkansson ◽  
Jonas Melke ◽  
Lars Westberg ◽  
Haydeh Niazi Shahabi ◽  
Silva Buervenich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Swedish Population ◽  
Val66met Polymorphism ◽  
Bdnf Val66met Polymorphism

scholarly journals The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

2021 ◽  
pp. 1-15
Author(s):  
Eduardo Tolosa ◽  
Georg Ebersbach ◽  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Angelo Antonini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impact Assessment ◽  
Real World ◽  
European Countries ◽  
Life Questionnaire ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Background: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. Objective: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the use of healthcare resources by people with PD and their carers. Methods: PRISM is an observational cross-sectional study, in which people with PD and their carers completed an online survey using structured questionnaires, including the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQuest) and Zarit Burden Interview (ZBI). Results: Data were collected from 861 people with PD (mean age, 65.0 years; mean disease duration, 7.7 years) and 256 carers from six European countries. People with PD reported a large number of different co-morbidities, non-motor symptoms (mean NMSQuest score, 12.8), and impaired HRQoL (median PDQ-39 summary score, 29.1). Forty-five percent of people with PD reported at least one impulse control behaviour. Treatment patterns varied considerably between different European countries. Levodopa was taken in the last 12 months by 85.9% of participants, and as monotherapy by 21.8% . Carers, who were mostly female (64.8%) and the partner/spouse of the person with PD (82.1%), reported mild to moderate burden (mean ZBI total score, 26.6). Conclusions: The PRISM study sheds light on the lives of people with PD and those who care for them, re-emphasising the many challenges they face in everyday life. The study also provides insights into the current treatment of PD in Europe.

Sign in / Sign up

Export Citation Format

Share Document